Condition: Transfusion-dependent β-thalassemia Patients · Sponsor: Rongrong Liu
β-thalassemia is one of the most common inherited hemoglobinopathies worldwide and a major public health issue that severely impacts birth quality, human health, and social progress. Currently, there are limited clinical drugs specifically designed to treat patients with β-thalassemia. This clinical trial aims to evaluate the efficacy and safety of luspatercept combined with low-dose thalidomide compared with luspatercept alone in patients with thalassemia. Key questions to be answered include: * Does luspatercept combined with low-dose thalidomide reduce the transfusion burden in patients with β-thalassemia major? * What medical problems may occur when patients receive luspatercept combined with low-dose thalidomide? In this clinical trial, participants were randomly assigned in a 1:1 ratio to either an intervention group (luspatercept combined with low-dose thalidomide) or a control group (luspatercept combined with placebo) using a central randomization system. The clinical efficacy and safety of the two groups were evaluated. The primary outcome measure was the clinical efficacy of luspatercept combined with low-dose thalidomide in reducing the transfusion burden in patients with β-thalassemia major.
This description comes directly from the study's public registry record.
Rongrong Liu · +86 0771 5356510 · liurongrong@stu.gxmu.edu.cn
Always discuss trial participation with your own doctor first.
| Southern Medical University Shenzhen Hospital | Shenzhen, Guangdong, China | Recruiting |
| Affiliated Hospital of Youjiang Medical College for Nationalities | Baise City, Guangxi, China | Recruiting |
| Baise People's Hospital | Baise City, Guangxi, China | Recruiting |
| Liuzhou People's Hospital | Liuzhou, Guangxi, China | Recruiting |
| Liuzhou Workers' Hospital | Liuzhou, Guangxi, China | Recruiting |
| Yulin First People's Hospital | Yulin, Guangxi, China | Recruiting |
| Yunnan Provincial First People's Hospital | Kunming, Yunnan, China | Recruiting |
| The First Affiliated Hospital of Guangxi Medical University | Naning, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07338344